M&A Deal Summary

Apellis Pharmaceuticals Acquires Potentia Pharmaceuticals

On November 20, 2014, Apellis Pharmaceuticals acquired life science company Potentia Pharmaceuticals

Acquisition Highlights
  • This is Apellis Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Apellis Pharmaceuticals’ 1st transaction in the United States.
  • This is Apellis Pharmaceuticals’ 1st transaction in Kentucky.

M&A Deal Summary
Date 2014-11-20
Target Potentia Pharmaceuticals
Sector Life Science
Buyer(s) Apellis Pharmaceuticals
Deal Type Add-on Acquisition

Target

Potentia Pharmaceuticals

Crestwood, Kentucky, United States
Potentia Pharmaceuticals is a biotechnology company, that focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the eye such as age-related macular degeneration.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Apellis Pharmaceuticals

Waltham, Massachusetts, United States
Category Company
Founded 2009
Sector Life Science
Employees702
Revenue 397M USD (2023)
DESCRIPTION

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company, focused on the development of a platform of novel therapeutic compounds for the treatment of a broad range of autoimmune diseases based upon complement immunotherapy. Uncontrolled complement activation can lead to a wide range of life-threatening or debilitating disorders. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. Apellis Pharmaceuticals was founded in 2009 and is headquartered in Waltham, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Kentucky) 1 of 1
Country (United States) 1 of 1
Year (2014) 1 of 1
Mergr

Product

Company

Legal